Step Pharma Set To Leap Into Clinic With CTPS1 Inhibitor
French Biotech Raises €35m
After a fresh cash injection, Step is ready to take STP938 for the treatment of T-cell blood cancers into Phase I trials in February.
You may also be interested in...
Private Company Edition: In addition to Adiso, Creyon recently launched with $40m and TRexBio extended its series A by $26m to $85m total. Also, Kurma Partners raised the first €160m of a planned €250m fund to back companies transitioning from R&D to commercial operations.
Despite being third to market behind Lilly’s Baqsimi and Xeris’s Gvoke to treat emergency episodes of hypoglycemia, Zealand is confident of a successful US launch for Zegalogue (dasiglucagon).
The embattled German major is touting a promising mid-stage thrombolytic but the spotlight this week has continued to shine on its business model and high levels of debt.